HANALL BIOPHARMA announced on the 22nd that last year's consolidated revenue amounted to 138.9 billion won, a 3% increase from the previous year, while operating profit fell to 230 million won, a decline of 89.6%. The net loss stood at 1.9 billion won.
In the fourth quarter of last year, operating profit turned positive at 2.7 billion won, compared to an operating loss of 4.3 billion won during the same period the previous year. Revenue and net income for the fourth quarter were recorded at 36.4 billion won and 1.5 billion won, respectively.
The company noted that sales of blockbuster products such as the probiotic pharmaceutical 'BioTop,' the prostate cancer and central precocious puberty treatment 'Eligard,' and the non-absorptive antibiotic 'Normix,' as well as specialized products in the hair loss and diabetes treatment categories, have increased.
The company continued its new drug development. The FcRn antibody HL161ANS, developed for the treatment of autoimmune diseases, entered a registration clinical trial for Graves' disease last year. The Parkinson's disease candidate compound HL192 achieved positive results in Phase 1 clinical trials. The dry eye treatment 'HL036,' jointly developed with Daewoong Pharmaceutical, entered its third Phase 3 clinical trial last year, aiming for topline results in 2026.
SEO Jung-won, CEO of HANALL BIOPHARMA, said, "In 2024, despite the challenging environment, we will continue to invest in research and development (R&D) for the future, and this year will be the year when the results of R&D investments bear fruit, making it a year of leap for us to become a global innovative pharmaceutical and biotech company."